{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T18:31:30Z","timestamp":1794508290174,"version":"4.9.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T00:00:00Z","timestamp":1704844800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T00:00:00Z","timestamp":1704844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>The purpose of this study was to determine whether the pan-immune-inflammation value (PIV), a novel biomarker combining neutrophil platelet, monocyte, and lymphocyte counts, some of the most widespread indicators of systemic inflammation, can predict mortality and prognosis in patients admitted to the intensive care unit (ICU) with septic shock.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>\n                      This prospective study was performed with 82 patients aged 18 or over admitted to a tertiary ICU with diagnoses of septic shock. Patients with hematological disease and neutropenia were excluded. PIV was calculated with the formula [neutrophil count (10\n                      <jats:sup>3<\/jats:sup>\n                      \/\u03bcL)\u2009\u00d7\u2009platelet count (10\n                      <jats:sup>3<\/jats:sup>\n                      \/\u03bcL)\u2009\u00d7\u2009monocyte count (10\n                      <jats:sup>3<\/jats:sup>\n                      \/\u03bcL)]\/lymphocyte count (10\n                      <jats:sup>3<\/jats:sup>\n                      \/\u03bcL).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Median age, presence of hypertension, Acute Physiology and Chronic Health Evaluation II (APACHE\u00a0II) levels, and neutrophil, monocyte, and platelet counts were lower in the low-PIV group than in the high-PIV group (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05). The highest area under ROC curve (AUC) was determined for Sequential Organ Failure Assessment (SOFA) (0.94 (0.89 \u2013 0.99)), followed by Glasgow Coma Scale (GCS) (0.81 (0.70 \u2013 0.91)), APACHE\u00a0II (0.80 (0.69 \u2013 0.91)) and lactate (0.77 (0.67 \u2013 0.88)). Median survival was longer in the low-PIV group than in the high-PIV group (28 (15.25 \u2013 40.76) vs 16 (9.46 \u2013 22.55) days, respectively,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05). The univariate Cox proportional hazards (CPH) model showed that high PIV (HR\u2009=\u20092.13 (1.03\u20144.38)), low GCS (HR\u2009=\u20093.31 (1.34 \u2013 8.15)), high SOFA (HR\u2009=\u20099.41 (2.86 \u2013 30.95)), high APACHE\u00a0II (HR\u2009=\u20093.08 (1.47 \u2013 6.45)), high lactate (HR\u2009=\u20096.56 (2.73 \u2013 15.75)), and high procalcitonin (PCT) (HR\u2009=\u20092.73 (1.11 \u2013 6.69)) values were associated with a decreased survival time among ICU patients (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05). The multivariate CPH model showed the age-adjusted risk estimates for these six laboratory parameters. High lactate (HR\u2009=\u20097.97 (2.19 \u2013 29.08)) and high SOFA scores (HR\u2009=\u20094.85 (1.22 \u2013 19.32)) were significantly associated with shorter survival in ICU patients (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The findings of this research suggest that PIV could predict the longer survival in patients with septic shock. Despite PIV score\u2019s capability to show inflammation, it is not significantly associated with mortality in the multivariate analysis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-023-08963-w","type":"journal-article","created":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T04:02:18Z","timestamp":1704859338000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["The prognostic importance of the pan-immune-inflammation value in patients with septic shock"],"prefix":"10.1186","volume":"24","author":[{"given":"Yasemin Bozkurt","family":"Turan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,10]]},"reference":[{"key":"8963_CR1","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1007\/s00134-021-06506-y","volume":"47","author":"L Evans","year":"2021","unstructured":"Evans L, Rhodes A, Alhazzani W, Antonelli M, Coopersmith CM, French C, et al. Surviving sepsis campaign: International guidelines for management of sepsis and septic shock 2021. Intensive Care Med. 2021;47:1181\u2013247.","journal-title":"Intensive Care Med"},{"issue":"9","key":"8963_CR2","doi-asserted-by":"publisher","first-page":"3188","DOI":"10.3390\/jcm12093188","volume":"12","author":"M Guarino","year":"2023","unstructured":"Guarino M, Perna B, Cesaro AE, Maritati M, Spampinato MD, Contini C, et al. 2023 Update on Sepsis and Septic Shock in Adult Patients: Management in the Emergency Department. J Clin Med. 2023;12(9):3188.","journal-title":"J Clin Med"},{"key":"8963_CR3","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1177\/0885066607301444","volume":"22","author":"M Piechota","year":"2007","unstructured":"Piechota M, Banach M, Irzmanski R, Barylski M, Piechota-Urbanska M, Kowalski J, et al. Plasma endothelin-1 levels in septic patients. J Intensive Care Med. 2007;22:232\u20139.","journal-title":"J Intensive Care Med"},{"key":"8963_CR4","doi-asserted-by":"publisher","first-page":"1036890","DOI":"10.3389\/fonc.2022.1036890","volume":"12","author":"XC Yang","year":"2022","unstructured":"Yang XC, Liu H, Liu DC, Tong C, Liang XW, Hui R. Prognostic value of pan-immune-inflammation value in colorectal cancer patients: A systematic review and meta-analysis. Front Oncol. 2022;12:1036890 Published online 2022 Dec 22.","journal-title":"Front Oncol."},{"key":"8963_CR5","doi-asserted-by":"publisher","first-page":"1099427","DOI":"10.3389\/fcvm.2023.1099427","volume":"10","author":"B Wu","year":"2023","unstructured":"Wu B, Zhang C, Lin S, Zhang Y, Ding S, Song W. The relationship between the pan-immune-inflammation value and long-term prognoses in patients with hypertension: National Health and Nutrition Examination Study, 1999\u20132018. Front Cardiovasc Med. 2023;10:1099427.","journal-title":"Front Cardiovasc Med"},{"issue":"11","key":"8963_CR6","doi-asserted-by":"publisher","first-page":"2675","DOI":"10.3390\/cancers14112675","volume":"14","author":"DC Guven","year":"2022","unstructured":"Guven DC, Sahin TK, Erul E, Kilickap S, Gambichler T, Aksoy S. The association between the pan-Immune-Inflammation value and cancer prognosis: A systematic review and meta-analysis. Cancers (Basel). 2022;14(11):2675.","journal-title":"Cancers (Basel)"},{"issue":"8","key":"8963_CR7","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.3390\/cancers13081964","volume":"13","author":"F Ligorio","year":"2021","unstructured":"Ligorio F, Fuc\u00e0 G, Zattarin E, Lobefaro R, Zambelli L, Leporati R, et al. The Pan-Immune-Inflammation-Value Predicts the Survival of Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Breast Cancer Treated With First-Line Taxane-Trastuzumab-Pertuzumab. Cancers. 2021;13(8):1964.","journal-title":"Cancers"},{"key":"8963_CR8","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.ejca.2021.03.043","volume":"150","author":"F Corti","year":"2021","unstructured":"Corti F, Lonardi S, Intini R, Salati M, Fenocchio E, Belli C, et al. The Pan-Immune-Inflammation Value in Microsatellite Instability-High Metastatic Colorectal Cancer Patients Treated With Immune Checkpoint Inhibitors. Eur J Cancer. 2021;150:155\u201367.","journal-title":"Eur J Cancer"},{"issue":"3","key":"8963_CR9","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1038\/s41416-020-0894-7","volume":"123","author":"G Fuc\u00e0","year":"2020","unstructured":"Fuc\u00e0 G, Guarini V, Antoniotti C, Morano F, Moretto R, Corallo S, et al. The Pan-Immune-Inflammation Value Is a New Prognostic Biomarker in Metastatic Colorectal Cancer: Results From a Pooled-Analysis of the Valentino and TRIBE First-Line Trials. Br J Cancer. 2020;123(3):403\u20139.","journal-title":"Br J Cancer"},{"issue":"12","key":"8963_CR10","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1016\/j.ijsu.2014.07.013","volume":"12","author":"E von Elm","year":"2014","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies. Int J Surg. 2014;12(12):1495\u20139.","journal-title":"Int J Surg"},{"issue":"12","key":"8963_CR11","doi-asserted-by":"publisher","first-page":"724443","DOI":"10.3389\/fimmu.2021.724443","volume":"29","author":"R Zeng","year":"2021","unstructured":"Zeng R, Liu F, Fang C, Yang J, Luo L, Yue P, et al. PIV and PILE Score at Baseline Predict Clinical Outcome of Anti-PD-1\/PD-L1 Inhibitor Combined With Chemotherapy in Extensive-Stage Small Cell Lung Cancer Patients. Front Immunol. 2021;29(12):724443.","journal-title":"Front Immunol"},{"issue":"15","key":"8963_CR12","doi-asserted-by":"publisher","first-page":"175883592311659","DOI":"10.1177\/17588359231165978","volume":"13","author":"L Provenzano","year":"2023","unstructured":"Provenzano L, Lobefaro R, Ligorio F, Zattarin E, Zambelli L, Sposetti C, et al. The pan-immune-inflammation value is associated with clinical outcomes in patients with advanced TNBC treated with first-line, platinum-based chemotherapy: an institutional retrospective analysis. Ther Adv Med Oncol. 2023;13(15):17588359231165978.","journal-title":"Ther Adv Med Oncol"},{"issue":"2","key":"8963_CR13","doi-asserted-by":"publisher","first-page":"88","DOI":"10.55563\/clinexprheumatol\/m46d0v","volume":"39 Suppl 129","author":"LE Lee","year":"2021","unstructured":"Lee LE, Ahn SS, Pyo JY, Song JJ, Park Y-B, Lee SW. Pan-immune-inflammation value at diagnosis independently predicts all-cause mortality in patients with antineutrophil cytoplasmic antibody-associated vasculitis. Clin Exp Rheumatol. 2021;39 Suppl 129(2):88\u201393.","journal-title":"Clin Exp Rheumatol."},{"issue":"15","key":"8963_CR14","doi-asserted-by":"publisher","first-page":"5413","DOI":"10.2147\/JIR.S385328","volume":"18","author":"E Topkan","year":"2022","unstructured":"Topkan E, Selek U, Kucuk A, Pehlivan B. Low Pre-ChemoradiotherapyPan-Immune-Inflammation Value (PIV) Measures Predict Better Survival Outcomes in Locally Advanced Pancreatic Adenocarcinomas. J Inflamm Res. 2022;18(15):5413\u201323. https:\/\/doi.org\/10.2147\/JIR.S385328. (PMID:36158517;PMCID:PMC9499729).","journal-title":"J Inflamm Res"},{"issue":"9","key":"8963_CR15","first-page":"3340","volume":"12","author":"E Kuperminc","year":"2023","unstructured":"Kuperminc E, Heming N, Carlos M, Annane D. Corticosteroids in ARDS. J. Clin Med. 2023;12(9):3340.","journal-title":"Clin Med"},{"issue":"3","key":"8963_CR16","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1002\/jso.20329","volume":"91","author":"SR Walsh","year":"2005","unstructured":"Walsh SR, Cook EJ, Goulder F, Justin TA, Keeling NJ. Neutrophil \u2013 lymphocyte ratio as a prognostic factor in colrectal cancer. J Surg Oncol. 2005;91(3):181\u20134.","journal-title":"J Surg Oncol"},{"issue":"6","key":"8963_CR17","doi-asserted-by":"publisher","first-page":"5996","DOI":"10.3390\/ijms24065996","volume":"24","author":"LA Vuillaume","year":"2023","unstructured":"Vuillaume LA, Lefebvre F, Benhamed A, Schnee A, Hoffmann M, Falcao FG, et al. Lymphocyte-to-C-Reactive Protein (LCR) Ratio Is Not Accurate to Predict Severity and Mortality in Patients with COVID-19 Admitted to the ED. Int J Mol Sci. 2023;24(6):5996.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"8963_CR18","doi-asserted-by":"publisher","first-page":"340","DOI":"10.3390\/toxins12050340","volume":"12","author":"M Girndt","year":"2020","unstructured":"Girndt M, Trojanowicz B, Ulrich C. Monocytes in uremia. Toxins (Basel). 2020;12(5):340.","journal-title":"Toxins (Basel)"},{"key":"8963_CR19","doi-asserted-by":"crossref","unstructured":"Zhang F, Li L, Wu X, Wen Y, Zhan X, Peng F, et al. Pan-immune-inflammation value is associated with poor prognosis in patients undergoing peritoneal dialysis.\u00a0Renal failure. 2023;45(1):2158103.","DOI":"10.1080\/0886022X.2022.2158103"},{"issue":"1","key":"8963_CR20","first-page":"5","volume":"102","author":"R Zahorec","year":"2001","unstructured":"Zahorec R. Ratio of neutrophil to lymphocyte counts\u2013rapid and simple parameter of systemic inflammation and stress in critically ill. Bratisl Lek Listy. 2001;102(1):5\u201314.","journal-title":"Bratisl Lek Listy"},{"issue":"5","key":"8963_CR21","doi-asserted-by":"publisher","first-page":"R192","DOI":"10.1186\/cc9309","volume":"14","author":"CPC de Jager","year":"2010","unstructured":"de Jager CPC, van Wijk PTL, Mathoera RB, de Jongh-Leuvenink J, van der Poll T, Wever PC. Lymphocytopenia and neutrophil-lymphocyte count ratio predict bacteremia better than conventional infection markers in an emergency care unit. Crit Care. 2010;14(5):R192.","journal-title":"Crit Care"},{"issue":"1","key":"8963_CR22","doi-asserted-by":"publisher","first-page":"e13872","DOI":"10.1111\/eci.13872","volume":"53","author":"B Murat","year":"2023","unstructured":"Murat B, Murat S, Ozgeyik M, Bilgin M. Comparison of pan-immune-inflammation value with other inflammation markers of long-term survival after ST-segment elevation myocardial infarction. Eur J Clin Invest. 2023;53(1):e13872.","journal-title":"Eur J Clin Invest"},{"issue":"5","key":"8963_CR23","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.1007\/s00405-022-07804-x","volume":"280","author":"DC Guven","year":"2023","unstructured":"Guven DC, Erul E, Yilmaz F, Yasar S, Yildirim HC, Ercan F, et al. The association between pan-immune-inflammation value and survival in head and neck squamous cell carcinoma. Eur Arch Otorhinolaryngol. 2023;280(5):2471\u20138.","journal-title":"Eur Arch Otorhinolaryngol"},{"issue":"12","key":"8963_CR24","doi-asserted-by":"publisher","first-page":"830138","DOI":"10.3389\/fonc.2022.830138","volume":"13","author":"F Lin","year":"2022","unstructured":"Lin F, Zhang L-P, Xie S-Y, Huang H-Y, Chen X-Y, Jiang T-C, et al. Pan-immune-inflammation value: a new prognostic index in operative breast cancer. Front Oncol. 2022;13(12):830138.","journal-title":"Front Oncol"},{"key":"8963_CR25","doi-asserted-by":"publisher","first-page":"1223786","DOI":"10.3389\/fonc.2023.1223786","volume":"13","author":"X Qi","year":"2023","unstructured":"Qi X, Qiao B, Song T, Huang D, Zhang H, Liu Y, et al. Clinical utility of the pan-immune-inflammation value in breast cancer patients. Front Oncol. 2023;13:1223786. https:\/\/doi.org\/10.3389\/fonc.2023.1223786. (eCollection 2023).","journal-title":"Front Oncol."},{"issue":"1","key":"8963_CR26","doi-asserted-by":"publisher","first-page":"e113","DOI":"10.1097\/AS9.0000000000000113","volume":"3","author":"Y Baba","year":"2021","unstructured":"Baba Y, Nakagawa S, Toihata T, Harada K, Iwatsuki M, Hayashi H, et al. Pan-immune-inflammation Value and Prognosis in Patients With Esophageal Cancer. Ann Surg Open. 2021;3(1):e113. https:\/\/doi.org\/10.1097\/AS9.0000000000000113. (eCollection 2022 Mar).","journal-title":"Ann Surg Open."}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-023-08963-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-023-08963-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-023-08963-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T16:13:15Z","timestamp":1774282395000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-023-08963-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,10]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["8963"],"URL":"https:\/\/doi.org\/10.1186\/s12879-023-08963-w","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,10]]},"assertion":[{"value":"7 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2025","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Editor's Note: Readers are alerted that the reliability of data presented in this article and informed consent from patients are currently in question. Appropriate editorial action will be taken once this matter is resolved.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2026","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Editor's Note: The institutional investigation concluded no ethics violation in this study. Therefore, no editorial action will be taken for this article.","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and the Guidelines for Good Clinical Practice. Written informed consent was obtained from all patients or their legal surrogates prior to inclusion.The Ethics Committee of the Faculty of Medicine of Marmara University approved the study (ethics number: 09.2022.1023).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"69"}}